- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Lewis C. Cantley, PhD
Director, Sandra and Edward Meyer Cancer Center,
Ronald P. Stanton Clinical Cancer Program at NewYork-Presbyterian
Margaret and Herman Sokol Professor in Oncology Research
Professor of Cancer Biology in Medicine
Weill Cornell Medical College
New York, New York
Seeking to understand the biochemical pathways that regulate normal cell growth and the defects that lead to cancer.
Laboratory studies are conducted to understand the effects of targeted therapy on the tumor microenvironment and to identify effective treatment strategies for TNBC tumors.
These studies will provide valuable information for the advancement of targated therapies for patients with triple negative breast cancer.
Triple negative breast cancer (TNBC) is a devastating disease. The goal of Dr. Cantley's laboratory is to develop effective treatment strategies to cure TNBC. They have developed experimental models that accurately recapitulate the diverse pathologic and genomic traits of the TNBC, making them ideal tools for preclinical studies.
In the last year his group 1) utilized a genomics-based approach to identify and target the specific genomic alterations observed in TNBC tumors; 2) analyzed genomic data to identify changes in the immune cell populations of the tumor microenvironment; 3) examined the effect of immuno-modulating therapies in TNBC.
In the coming year they will build upon their previous work to examine how targeted therapy impacts the immune cells in the tumor microenvironment and expand their precision medicine approach to identify effective treatment strategies for each individual tumor. This information will be valuable to new strategies to extend the lives of more patients.
Lewis C. Cantley, PhD, is the Margaret and Herman Sokol Professor and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College/Ronald P. Stanton Clinical Cancer Program at New York Presbyterian Hospital. Dr. Cantley grew up in West Virginia and graduated from West Virginia Wesleyan College in 1971. He obtained a PhD in biophysical chemistry from Cornell University in 1975 and did postdoctoral training at Harvard University. Prior to taking the position at Weill Cornell, he taught and did research in biochemistry, physiology and cancer biology in Boston, most recently at Beth Israel Deaconess Medical Center and Harvard Medical School. His laboratory discovered the PI 3-Kinase pathway that plays a critical role in insulin signaling and in cancers.
Dr. Cantley was elected to the Institute of Medicine in 2014, to the National Academy of Sciences in 2001 and to the American Academy of Arts and Sciences in 1999. Among his other awards are the ASBMB Avanti Award for Lipid Research in 1998, the Heinrich Wieland Preis for Lipid Research in 2000, the Caledonian Prize from the Royal Society of Edinburgh in 2002, the 2005 Pezcoller Foundation–AACR International Award for Cancer Research, the 2009 Rolf Luft Award for Diabetes and Endocrinology Research from the Karolinska Institute, Stockholm, the 2011 Pasrow Prize for Cancer Research, the 2013 Breakthrough in Life Sciences Prize and the 2013 Jacobaeus Prize for Diabetes Research from the Karolinska Institute and the 2015 AACR Princess Takamatsu Memorial Lectureship.